CN1321153A - 端粒酶抑制剂及其使用方法 - Google Patents
端粒酶抑制剂及其使用方法Info
- Publication number
- CN1321153A CN1321153A CN00801875A CN00801875A CN1321153A CN 1321153 A CN1321153 A CN 1321153A CN 00801875 A CN00801875 A CN 00801875A CN 00801875 A CN00801875 A CN 00801875A CN 1321153 A CN1321153 A CN 1321153A
- Authority
- CN
- China
- Prior art keywords
- compound
- thiazolidine
- composition
- diketone
- benzylidyne
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/34—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/36—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14217399P | 1999-07-01 | 1999-07-01 | |
JP187616/1999 | 1999-07-01 | ||
JP18761699 | 1999-07-01 | ||
US60/142,173 | 1999-07-01 | ||
JP30757699A JP2001072592A (ja) | 1999-07-01 | 1999-10-28 | テロメラーゼ阻害剤 |
JP307576/1999 | 1999-10-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN1321153A true CN1321153A (zh) | 2001-11-07 |
Family
ID=27325921
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN00801875A Pending CN1321153A (zh) | 1999-07-01 | 2000-06-30 | 端粒酶抑制剂及其使用方法 |
Country Status (9)
Country | Link |
---|---|
EP (1) | EP1109796A1 (fr) |
JP (1) | JP2003507473A (fr) |
KR (1) | KR20010099634A (fr) |
CN (1) | CN1321153A (fr) |
AU (1) | AU6340600A (fr) |
CA (1) | CA2341253A1 (fr) |
HK (1) | HK1043113A1 (fr) |
ID (1) | ID29875A (fr) |
WO (1) | WO2001002377A1 (fr) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103804371A (zh) * | 2008-07-02 | 2014-05-21 | 阿斯利康(瑞典)有限公司 | 化合物251 |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1376150A (zh) * | 1999-07-26 | 2002-10-23 | 盐野义制药株式会社 | 具有血栓形成素受体拮抗作用的药物组合物 |
DE60115132T2 (de) * | 2000-04-21 | 2006-07-06 | Pfizer Products Inc., Groton | Thyroid-Rezeptorliganden |
US6620830B2 (en) | 2000-04-21 | 2003-09-16 | Pfizer, Inc. | Thyroid receptor ligands |
EP1276730A2 (fr) * | 2000-04-24 | 2003-01-22 | ARYx Therapeutics | Compositions et methodes destinees au traitement du diabete, de l'hyperlipidemie, de l'hypercholesterolemie et de l'atherosclerose |
US6958355B2 (en) | 2000-04-24 | 2005-10-25 | Aryx Therapeutics, Inc. | Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis |
US6768008B2 (en) * | 2000-04-24 | 2004-07-27 | Aryx Therapeutics | Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis |
US6784199B2 (en) | 2000-09-21 | 2004-08-31 | Aryx Therapeutics | Isoxazolidine compounds useful in the treatment of diabetes, hyperlipidemia, and atherosclerosis in mammals |
US6680387B2 (en) | 2000-04-24 | 2004-01-20 | Aryx Therapeutics | Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis |
DE10133665A1 (de) * | 2001-07-11 | 2003-01-30 | Boehringer Ingelheim Pharma | Carbonsäurederivate, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Herstellung |
WO2003018011A1 (fr) | 2001-08-24 | 2003-03-06 | Wyeth Holdings Corporation | 5-(substitue)-5-(substitue sulfonyl ou sulfanyl)thiazolidine-2,4-diones utiles pour l'inhibition de la farnesyl-proteine transferase |
US7045523B2 (en) | 2001-10-18 | 2006-05-16 | Novartis Ag | Combination comprising N-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine and telomerase inhibitor |
GB0204252D0 (en) * | 2002-02-23 | 2002-04-10 | Oxford Glycosciences Uk Ltd | Novel compounds |
WO2004028535A1 (fr) * | 2002-09-26 | 2004-04-08 | Pintex Pharmaceuticals, Inc. | Composes de modulation de pin-1 et leurs procedes d'utilisation |
US7781464B2 (en) * | 2003-01-17 | 2010-08-24 | Bexel Pharmaceuticals, Inc. | Heterocyclic diphenyl ethers |
US6794401B2 (en) | 2003-01-17 | 2004-09-21 | Bexel Pharmaceuticals, Inc. | Amino acid phenoxy ethers |
US7521465B2 (en) | 2003-01-17 | 2009-04-21 | Bexel Pharmaceuticals, Inc. | Diphenyl ether derivatives |
WO2004093803A2 (fr) * | 2003-04-16 | 2004-11-04 | Pintex Pharmaceuticals, Inc. | Composes photochimiotherapeutiques utilises dans le traitement d'etats associes a pin1 |
US7087576B2 (en) | 2003-10-07 | 2006-08-08 | Bexel Pharmaceuticals, Inc. | Dipeptide phenyl ethers |
FI20041129A0 (fi) * | 2004-08-30 | 2004-08-30 | Ctt Cancer Targeting Tech Oy | Tioksotiatsolidinoniyhdisteitä lääkkeinä käytettäviksi |
CA2580811C (fr) | 2004-09-28 | 2014-04-08 | Otsuka Pharmaceutical Co., Ltd. | Derive de carbostyrile |
FR2887444A1 (fr) * | 2005-06-28 | 2006-12-29 | Oreal | Composes benzylidene-1,3-thiazolidine-2,4-diones, leurs utilisations et compositions pour stimuler ou induire la pousse des fibres keratiniques et/ou freiner leur chute et/ou augmenter leur densite. |
KR100814109B1 (ko) | 2006-01-09 | 2008-03-14 | 한국생명공학연구원 | 로다닌 유도체, 이의 제조방법 및 이를 유효성분으로함유하는 약학적 조성물 |
TWI315304B (en) * | 2006-08-31 | 2009-10-01 | Univ Taipei Medical | Indoline-sulfonamides compounds |
WO2008109731A2 (fr) * | 2007-03-07 | 2008-09-12 | Jassen Pharmaceutica N.V. | Phénoxythiazolidinediones n-alkylées en tant que modulateurs du récepteur-α œstrogénique |
EP2217235A4 (fr) * | 2007-11-15 | 2011-01-12 | Musc Found For Res Dev | Inhibiteurs de protéines kinases pim, compositions et procédés pour traiter le cancer |
CN101973893B (zh) * | 2010-09-07 | 2013-07-17 | 黑龙江省科学院石油化学研究院 | 4-[2-(1-苯乙烯基)]-n,n-二(4-溴苯基)苯胺的合成方法 |
KR101817287B1 (ko) * | 2016-01-08 | 2018-01-10 | 조선대학교 산학협력단 | 티아졸리딘디온 유도체 및 그의 용도 |
CN116217511B (zh) * | 2023-03-22 | 2024-04-19 | 沈阳药科大学 | 一种双靶点化合物及其制备方法和在制备sEH抑制剂与PPARs激动剂中的应用 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5522636A (en) * | 1978-08-04 | 1980-02-18 | Takeda Chem Ind Ltd | Thiazoliding derivative |
JPS5697277A (en) * | 1980-01-07 | 1981-08-05 | Takeda Chem Ind Ltd | Thiazolidine derivative |
JPS58118577A (ja) * | 1982-01-07 | 1983-07-14 | Takeda Chem Ind Ltd | チアゾリジン誘導体 |
CN1003445B (zh) * | 1984-10-03 | 1989-03-01 | 武田药品工业株式会社 | 噻唑烷二酮衍生物,其制备方法和用途 |
AR240698A1 (es) * | 1985-01-19 | 1990-09-28 | Takeda Chemical Industries Ltd | Procedimiento para preparar compuestos de 5-(4-(2-(5-etil-2-piridil)-etoxi)benzil)-2,4-tiazolidindiona y sus sales |
US4738972A (en) * | 1985-05-21 | 1988-04-19 | Pfizer Inc. | Hypoglycemic thiazolidinediones |
US4812570A (en) * | 1986-07-24 | 1989-03-14 | Takeda Chemical Industries, Ltd. | Method for producing thiazolidinedione derivatives |
WO1989008650A1 (fr) * | 1988-03-08 | 1989-09-21 | Pfizer Inc. | Agents hypoglycemiques de thiazolidinedione |
WO1989008651A1 (fr) * | 1988-03-08 | 1989-09-21 | Pfizer Inc. | Derives de thiaxolidinedione hypoglycemiques |
IE940525L (en) * | 1988-05-25 | 1989-11-25 | Warner Lambert Co | Known and selected novel arylmethylenyl derivatives of¹thiazolidinones, imidazolidinones and oxazolidinones useful¹as antiallergy agents and antiinflammatory agents |
US5143929A (en) * | 1991-05-09 | 1992-09-01 | Warner-Lambert Company | 2-substituted thiazolidinone, oxazolidinone, and imidazolidinone derivatives of fenamates as antiinflammatory agents |
US6251928B1 (en) * | 1994-03-16 | 2001-06-26 | Eli Lilly And Company | Treatment of alzheimer's disease employing inhibitors of cathepsin D |
US5814647A (en) * | 1997-03-04 | 1998-09-29 | Board Of Regents, The University Of Texas System | Use of troglitazone and related compounds for the treatment of the climacteric symptoms |
-
2000
- 2000-06-30 JP JP2001518671A patent/JP2003507473A/ja not_active Withdrawn
- 2000-06-30 KR KR1020017002632A patent/KR20010099634A/ko not_active Application Discontinuation
- 2000-06-30 CA CA002341253A patent/CA2341253A1/fr not_active Abandoned
- 2000-06-30 WO PCT/US2000/018211 patent/WO2001002377A1/fr not_active Application Discontinuation
- 2000-06-30 CN CN00801875A patent/CN1321153A/zh active Pending
- 2000-06-30 ID IDW20010734A patent/ID29875A/id unknown
- 2000-06-30 AU AU63406/00A patent/AU6340600A/en not_active Abandoned
- 2000-06-30 EP EP00950282A patent/EP1109796A1/fr not_active Withdrawn
-
2002
- 2002-04-18 HK HK02102943.2A patent/HK1043113A1/zh unknown
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103804371A (zh) * | 2008-07-02 | 2014-05-21 | 阿斯利康(瑞典)有限公司 | 化合物251 |
Also Published As
Publication number | Publication date |
---|---|
CA2341253A1 (fr) | 2001-01-11 |
WO2001002377A9 (fr) | 2001-10-11 |
EP1109796A1 (fr) | 2001-06-27 |
JP2003507473A (ja) | 2003-02-25 |
WO2001002377A1 (fr) | 2001-01-11 |
HK1043113A1 (zh) | 2002-09-06 |
AU6340600A (en) | 2001-01-22 |
KR20010099634A (ko) | 2001-11-09 |
ID29875A (id) | 2001-10-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1321153A (zh) | 端粒酶抑制剂及其使用方法 | |
CN1152863C (zh) | 作为环氧合酶-2选择性抑制剂的取代的吡啶类化合物及其组合物 | |
CN1234358C (zh) | 苯并噻唑衍生物 | |
CN1324014C (zh) | 用作pde4抑制剂的哒嗪-3(2h)-酮衍生物、制备方法以及其组合物和用途 | |
CN1146542C (zh) | 苯甲酰胺衍生物及其作为细胞因子抑制剂的用途 | |
CN1203066C (zh) | 作为环加氧酶-2抑制剂的(甲磺酰基)苯基-2-(5h)-呋喃酮 | |
CN100338061C (zh) | 炔-芳基磷酸二酯酶-4抑制剂 | |
CN1178932C (zh) | 酰胺衍生物 | |
CN1230421C (zh) | 酰胺化合物及其药物用途 | |
CN1259307C (zh) | 酰化的二氢化茚基胺及其作为药物的用途 | |
CN1142912C (zh) | 用作细胞因子产生的抑制剂的酰胺衍生物 | |
CN1239485C (zh) | 作为IL-1β和TNF-α抑制剂的二苯酮类 | |
CN1046721C (zh) | 杂环化合物及其制备方法和用途 | |
CN1520296A (zh) | 作为葡糖激酶(glk)调制剂的氨基烟酸盐衍生物 | |
CN1642915A (zh) | 用作组蛋白脱乙酰基酶抑制剂的苯甲酰胺衍生物 | |
CN1227555A (zh) | 细胞因子生成抑制剂、三氮䓬化合物及其中间体 | |
CN1678586A (zh) | 取代的喹啉ccr5受体拮抗剂 | |
CN1170827C (zh) | 苯并呋喃基吡喃酮衍生物 | |
CN1863777A (zh) | 抑制香草素受体亚型1(vr1)受体的稠合氮杂二环化合物 | |
CN1505613A (zh) | 取代的吲哚、含这类吲哚的药物组合物及它们作为PPAR-γ结合剂的用途 | |
CN1662236A (zh) | 组蛋白脱乙酰基转移酶抑制剂 | |
CN1798738A (zh) | 作为钠通道阻滞剂的联芳基取代吡唑 | |
CN1960975A (zh) | 作为多聚(adp-核糖)聚合酶(parp)抑制剂的取代的吡啶酮 | |
CN1089947A (zh) | 新的杂环化合物 | |
CN1539816A (zh) | Il-8受体拮抗剂 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
WD01 | Invention patent application deemed withdrawn after publication | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1043113 Country of ref document: HK |